基本信息
浏览量:495
职业迁徙
个人简介
Research Description
My major research interests are in the development of HIV-1-based vaccines for China and of a relevant animal model for vaccine testing and pathogenesis studies. My current focus is on the generation and characterization of multivalent AIDS vaccines using a live modified vaccinia Tiantan (MVTT) strain as well as novel strategies of antigen-targeting to dendritic cells (DC). For these purposes, I have designed and constructed several attenuated yet replicating MVTT vectors for better antigen delivery and vaccinia production. Using them, we were able to generate a single recombinant vaccinia MVTT virus to deliver three SIV genes (env and gag-pol). Preliminary testing in monkeys has shown that the virus can induce stronger cell-mediated and antibody responses to all three SIV gene products, which conferred significant protection against intrarectal SIVmac239 challenge. As a preventive means, I will further develop, optimize, and eventually test MVTT-based vaccine in humans in the near future. Meantime, we have successfully discovered a new way of antigen-targeting to dendritic cells. Using soluble PD1 as a targeting molecule, we were able to elicit high frequency of polyfunctional HIV Gag-specific CD8+ T cells, which confer significant protection against pathogenic viral infection and therapeutic cure of malignant mesothelioma in mice. For the assessment of the vaccine efficacy, I am also actively investigating HIV evolution in China. Doing this study over several years, we will gain crucial prevalent and incident rate data that will be essential for our future vaccine testing in humans. Furthermore, I have also established the first R5-dependent SHIV/macaque models using subtype C and B’ envelopes. Since these viruses can be transmitted to virus-naïve monkeys atraumatically via the intravaginal route, we can mimic the dominant mode of HIV-1 spread in humans and apply the model to relevant questions. For example, I will use this new animal model to test the efficacy of HIV subtype C Env-based vaccines. The model may also be used for cross-subtype challenge or microbicides testing. In addition, using vaccinia MVTT-based and novel antigen-targeting systems, we are constructing vaccines against SARS-CoV, Influenza and TB infections as well as immunotherapies against cancer.
My major research interests are in the development of HIV-1-based vaccines for China and of a relevant animal model for vaccine testing and pathogenesis studies. My current focus is on the generation and characterization of multivalent AIDS vaccines using a live modified vaccinia Tiantan (MVTT) strain as well as novel strategies of antigen-targeting to dendritic cells (DC). For these purposes, I have designed and constructed several attenuated yet replicating MVTT vectors for better antigen delivery and vaccinia production. Using them, we were able to generate a single recombinant vaccinia MVTT virus to deliver three SIV genes (env and gag-pol). Preliminary testing in monkeys has shown that the virus can induce stronger cell-mediated and antibody responses to all three SIV gene products, which conferred significant protection against intrarectal SIVmac239 challenge. As a preventive means, I will further develop, optimize, and eventually test MVTT-based vaccine in humans in the near future. Meantime, we have successfully discovered a new way of antigen-targeting to dendritic cells. Using soluble PD1 as a targeting molecule, we were able to elicit high frequency of polyfunctional HIV Gag-specific CD8+ T cells, which confer significant protection against pathogenic viral infection and therapeutic cure of malignant mesothelioma in mice. For the assessment of the vaccine efficacy, I am also actively investigating HIV evolution in China. Doing this study over several years, we will gain crucial prevalent and incident rate data that will be essential for our future vaccine testing in humans. Furthermore, I have also established the first R5-dependent SHIV/macaque models using subtype C and B’ envelopes. Since these viruses can be transmitted to virus-naïve monkeys atraumatically via the intravaginal route, we can mimic the dominant mode of HIV-1 spread in humans and apply the model to relevant questions. For example, I will use this new animal model to test the efficacy of HIV subtype C Env-based vaccines. The model may also be used for cross-subtype challenge or microbicides testing. In addition, using vaccinia MVTT-based and novel antigen-targeting systems, we are constructing vaccines against SARS-CoV, Influenza and TB infections as well as immunotherapies against cancer.
研究兴趣
论文共 476 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGYno. 2 (2024): 162-171
JOURNAL OF VIROLOGYpp.e0024224-e0024224, (2024)
SENSORS AND ACTUATORS B-CHEMICAL (2024): 134803-134803
Na Liu,Runhong Zhou,Anthony Raymond Tam, Wing- Ming Chu,Dawei Yang,Haode Huang,Qiaoli Peng,Zhenglong Du,Bohao Chen, Kelvin Kai-Wang To,Zhiwei Chen
CLINICAL IMMUNOLOGY (2024): 109900-109900
Clinical and Experimental Obstetrics & Gynecologyno. 4 (2024)
Infectious diseases of povertyno. 1 (2023): 66
引用0浏览0WOS引用
0
0
Journal of Immunologyno. 1 (2023): 171.15-171.15
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn